NASDAQ:ATHE Alterity Therapeutics - ATHE News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. $3.91 +0.10 (+2.62%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.80▼$3.9750-Day Range$2.95▼$4.2952-Week Range$2.90▼$10.50Volume25,947 shsAverage Volume22,031 shsMarket Capitalization$15.68 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHE Media Mentions By Week ATHE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHE News Sentiment▼0.620.72▲Average Medical News Sentiment ATHE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHE Articles This Week▼30▲ATHE Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophyfinance.yahoo.com - January 25 at 8:28 AMAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophyfinance.yahoo.com - January 9 at 3:15 PMAlterity Therapeutics to implement 1-for-10 reverse ADS splitmsn.com - January 7 at 10:58 AMAlterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)finance.yahoo.com - January 6 at 12:16 PMAlterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forumfinance.yahoo.com - January 3 at 12:42 PMAlterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meetingfinance.yahoo.com - November 7 at 3:14 PMAppendix 4C - Q1 FY23 Quarterly Cash Flow Reportfinance.yahoo.com - November 5 at 5:45 AMAlterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meetingfinance.yahoo.com - October 26 at 11:50 AMAlterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disordersfinance.yahoo.com - September 26 at 9:47 AMAlterity Therapeutics Gets FDA Approval for IND Application for ATH434marketwatch.com - September 20 at 5:06 PMAlterity Gets FDA Nod To Conduct Phase 2 Trial Of ATH434 In Multiple System Atrophynasdaq.com - September 20 at 5:06 PMAlterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophyfinance.yahoo.com - September 20 at 5:06 PMAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europefinance.yahoo.com - August 25 at 7:33 AMAlterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Reportfinance.yahoo.com - July 22 at 11:02 AMAlterity wins Italian nod to study lead asset in Parkinsonian disorderseekingalpha.com - June 23 at 5:40 PMLife Sciences Investor Forum: Company Executives Present Live June 23rdfinance.yahoo.com - June 21 at 8:41 AMAlterity Therapeutics to Present at the VirtualInvestorConferences.com Life Sciences Investor Forumfinance.yahoo.com - June 20 at 7:39 AMAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophyfinance.yahoo.com - June 2 at 10:54 AMAlterity gsts UK drug regulator nod for phase 2 study of ATH434 for multiple system atrophyseekingalpha.com - April 27 at 10:34 AMAlterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdomfinance.yahoo.com - April 27 at 10:34 AMAlterity Therapeutics to Present at the 34th Annual Roth Conferencefinance.yahoo.com - March 7 at 11:36 AMAlterity Therapeutics Limited American Depositary Shares (ATHE)nasdaq.com - February 14 at 12:06 AMAlterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Diseasefinance.yahoo.com - January 28 at 6:39 PMAlterity announces publication of animal study on lead assetseekingalpha.com - January 28 at 8:05 AMAlterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Diseasefinance.yahoo.com - January 28 at 8:05 AMAppendix 4C - Q2 FY22 Quarterly Cash Flow Reportfinance.yahoo.com - January 27 at 8:39 AMPre-market Movers: KAVL, ATHE, BLI, PSTV, CNSP…markets.businessinsider.com - January 6 at 8:43 AMAlterity Therapeutics wins U.S. patent related to neurological diseasesseekingalpha.com - January 6 at 8:43 AMAlterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer'sfinance.yahoo.com - January 6 at 8:43 AMAlterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conferencefinance.yahoo.com - January 5 at 9:54 AMAlterity Therapeutics to Participate in Two Upcoming Investor Conferencesfinance.yahoo.com - November 22 at 8:31 AMAlterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021finance.yahoo.com - November 9 at 9:51 AMAlterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseasesfinance.yahoo.com - November 4 at 8:46 AMAppendix 4C - Q1 FY22 Quarterly Cash Flow Reportfinance.yahoo.com - October 29 at 9:00 AMATHE, NMTR and PXLW among pre among gainersseekingalpha.com - August 22 at 3:36 PM99 Biggest Movers From Yesterdaymsn.com - August 6 at 10:01 AMThinking about buying stock in Exela Technologies, Alterity Therapeutics, Farmmi, Micron Technology, or Under Armour?marketwatch.com - August 5 at 8:18 AMAlterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson'sfinance.yahoo.com - August 4 at 9:44 AMAppendix 4C - Q4 FY21 Quarterly Cash Flow Reportfinance.yahoo.com - July 30 at 1:23 PMAlterity Therapeutics Says Treatment With ATH434 Neuroprotective And Improved Motor Functionmarkets.businessinsider.com - July 15 at 12:29 PMPre-market Movers: ATHE, HUDI, VERB, SGOC, IMUX…markets.businessinsider.com - July 15 at 7:29 AMAlterity Therapeutics shares rise as its new US patent supports bid to find treatment for Alzheimer's and Parkinson'sproactiveinvestors.com.au - July 1 at 6:03 PMWant to Buy Alterity Therapeutics (ATHE) Stock? See This First.finance.yahoo.com - July 1 at 6:03 PMWhat's Sending Alterity Therapeutics Shares Higher?benzinga.com - July 1 at 1:03 PMAlterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson'sfinance.yahoo.com - July 1 at 8:02 AMAlterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trialfinance.yahoo.com - June 23 at 9:51 AMAlterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - June 7 at 7:25 PMAlterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Reportfinance.yahoo.com - April 29 at 8:47 AMAlterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorderfinance.yahoo.com - April 21 at 1:22 PM24 Stocks Moving in Wednesday's Pre-Market Sessionmsn.com - April 21 at 8:21 AM Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ATHE) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.